The Twitterverse's Biotech Stock Picks for 2013

@adamfeuerstein celgene? Most undervalued mega biotech on the market? I only play with options though— SAmitBhatt (@SamitBhatt) January 1, 2013

IDIX - my bet is -184 and the other G 'nuc' are dead, even allowed by FDA, waste of money - play on NS5A and 7977 royalties— Sport234a2b (@Sport234a) January 1, 2013

@adamfeuerstein I share your healthy skepticism for Arena Pharmaceuticals but I predict their launch of Belviq will not be a disaster.— Matthew C. MacIsaac (@macissm) January 1, 2013

@adamfeuerstein $AMRN no b/o but partnership deal. $VICL primary endpoint misses but overall survival data +. $SRPT accelerated approval.— Bobby Shea (@robertcshea) January 1, 2013

@adamfeuerstein prediction part 1:Buyside continues to dabble in crossover investing in private biotech, but...— k bosley (@ksbosley) January 1, 2013

@adamfeuerstein part 2: ...starting to feel tension re post$ valuations on their private investments vs wanting to still keep IPO val'ns low— k bosley (@ksbosley) January 1, 2013

@adamfeuerstein More partnering w/ patient-led venture philanthropy for rare diseases. Hopefully Pharma won't just exploit as cheap funding.— Oli Rayner (@oli_rayner) January 1, 2013

@adamfeuerstein big year for $OPK diagnostics platforms— Raymond Gachette (@raygachette) January 1, 2013

@adamfeuerstein $NAVB will be approved and will be SOC replacing blue dye, for most part, by end of year. Cardinal will buy out.— Tobin Michael (@TobinMichael1) January 1, 2013

@adamfeuerstein $ECYT conditional EU approval bullish tubulysin data late 2013. $AFFY Omontys will continue to gain traction.— Olddogwithnewtrix (@olddoggnewtrix) January 1, 2013

@kokurasluck @adamfeuerstein happy new year guys.My prediction is obvious, but I will add, strength of data will shock investor world. $CLSN— Siavoche (@Magicsia) January 1, 2013

@adamfeuerstein I predict $clsn fails but true believers like @magicsia never give up the dream— Stock Jock (@hedgeorbehedged) January 1, 2013

@adamfeuerstein CELG will finally break out. Exorbinant drug pricing and fraud and abuse in the health care system wil come to prominence.— William A. Wolkstein (@medtechmd) January 1, 2013

@adamfeuerstein prediction both ARNA and vvus fail miserably and their stocks trade for the cash on b.s. by yr end— Rafa (@coffee_junkies) January 1, 2013

@adamfeuerstein Envouraged by the positive performance of new IPOs, biotechs start reconsidering going public as a viable exit— Vikram Khanna (@VikramKhanna_) January 1, 2013

@adamfeuerstein I would look at $INCY value has not changed much since jakafi approved, data evolving from RA drug looking VG,maybe LLY acq?— Db (@hydrogenblimp) January 1, 2013

@adamfeuerstein .. and $arry & $cldx goes up from current levels maybe bought out andmy upset for theyear $rtrx does succeed in its p2— Joan Bar (@JoanBar2) January 1, 2013

@adamfeuerstein General: 2013 could be record year for sector M,P(partnerships)&A.— Mike Huckman (@MikeHuckman) January 1, 2013

@adamfeuerstein Two new options for MS patients with Lemtrada and BG12.Talon following Amarin &launching Marqibo alone.— gansubpodar (@gansubpodar) January 1, 2013

@adamfeuerstein $BMRN— Michael Scally (@michaelscally) January 1, 2013

@adamfeuerstein $SGMO hits one target after another,becoming the gene therapy platform of choice: lot of headache for many pharma firms— Ralph (@StuckInStock) January 1, 2013

@adamfeuerstein $PRAN and Alzheimer's / Huntington data in 2013.— nixon786 (@nixon786) January 1, 2013

@adamfeuerstein based on upcoming catalysts, I think it's possible, with multiple + data scenarios, $ANAC sees new highs in 2013— TheEscapeGroup (@TheEscapeGroup) January 1, 2013

@adamfeuerstein big year for srpt and Aegr. Srpt gets accelerated approval. Aegr gets emea approval. FDA rejects Isis.— Joe Smith (@zwerp2000) January 1, 2013

@adamfeuerstein on + side, I expect $ navb to get earlier approval for seek and finally make some meaningful progress on another compound— Joe Chik (@Drchik23) January 1, 2013

@adamfeuerstein on - side, $kerx gets closer to fading away. Even if results are good--btw where r they--drug loses out to competitors— Joe Chik (@Drchik23) January 1, 2013

@adamfeuerstein Xtandi peak sales estimates revised downwards in Q2/3 due to PrCa *treatment* market being smaller than originally thought— Vikram Khanna (@VikramKhanna_) January 1, 2013

@adamfeuerstein $BSX will continue to disappoint in 2013— David Bailey (@DavidBailey2012) January 1, 2013

@adamfeuerstein Lyxumia (Sanofi's GLP-1) gets approved in US.Big for Zealand Pharma.Insulin battle heats up with Tresiba from Novo.— gansubpodar (@gansubpodar) January 1, 2013

@adamfeuerstein $ONXX makes a big acquisition or gets acquired— Vikram Khanna (@VikramKhanna_) January 1, 2013

IMO, in 13, big caps bios underperform vs index, midcap inline w/mkt, most fun/riskiest/upside/downside bets all over the speculative names.— Sport234a2b (@Sport234a) January 1, 2013

@adamfeuerstein Serada gets positive AdCom vote and FDA approval.$DEPO.— happycamper (@happyycamperr) January 1, 2013

@adamfeuerstein In 2013, the ineffectiveness of FOBT for CRC screening will be made evident, and $EXAS will become "The Rule for theStool"— Phil Kobi (@PhilKobi) January 1, 2013

@adamfeuerstein HZNP will double from here...— Aric Best (@thegunnerab) January 1, 2013

-- Reported by Adam Feuerstein in Boston.

Follow @AdamFeuerstein

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

« First ‹ Previous 1 2